BioCentury
ARTICLE | Company News

Teva buying majority stake in Immuneering

August 4, 2015 12:53 AM UTC

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will acquire a 51% stake in computational genomic analysis company Immuneering Corp. (Cambridge, Mass.). Teva spokesperson Denise Bradley said Teva will pay Immunoneering $45 million in three tranches, and will receive exclusive right of first refusal for Immuneering projects addressing CNS disorders.

Immuneering analyzes genomic and proteomic data to generate hypotheses and design follow-up studies for compounds in development. Last year, the companies co-authored a study comparing transcriptional responses to Teva's multiple sclerosis drug Copaxone glatiramer acetate versus a generic formulation. ...